All Stories

  1. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients
  2. Smoldering multiple myeloma: to treat or not to treat
  3. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well
  4. Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation
  5. High-dose chemotherapy for germ cell tumors: do we have a model?
  6. Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study
  7. Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients
  8. Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs
  9. Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry
  10. Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization
  11. An old drug with a new future: bendamustine in multiple myeloma
  12. Diagnostic approaches for identifying acute graft-versus-host disease: what comes next?
  13. Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents
  14. Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma
  15. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma
  16. Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program
  17. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients